



# Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 13<sup>th</sup> February, 2025

**The President**  
**Corporate Relationship Department**  
**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**25<sup>th</sup> Floor, Dalal Street,**  
**Mumbai 400 001**

**The Vice President,**  
**Listing Compliance Department,**  
**National Stock Exchange of India Limited,**  
**Exchange Plaza, 5<sup>th</sup> Floor**  
**Plot No. C/2, G-Block,**  
**Bandra Kurla Complex, Bandra (E),**  
**Mumbai 400 051**

**ISIN: INE915B01019**  
**BSE Scrip Code: 532305**

**NSE Symbol: INDSWFTLAB**

**SUB: OUTCOME OF ADJOURNED BOARD MEETING HELD ON 13<sup>TH</sup> FEBRUARY, 2025**

Dear Sir/Ma'am,

Pursuant to the provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter "SEBI Listing Regulations") we wish to inform you that the Board of Directors of the Company at their adjourned Board Meeting held today i.e., Thursday, 13<sup>th</sup> February, 2025, have considered and inter-alia approved the following business items: -

1. Standalone and Consolidated Un-Audited Financial Results of Ind-Swift Laboratories Limited for the Quarter and Nine-Months ended 31<sup>st</sup> December 2024 along with the Limited Review Report as submitted by the Statutory Auditors is enclosed herewith as Annexure-I.
2. Appointment of Sh. Vishal Arora, Practicing Company Secretary as the Secretarial Auditor of the company for conducting secretarial audit for the financial year 2024-2025. (Annexure-II)
3. Appointment of M/s. Jain & Associates, Chartered Accountants as Internal Auditors of the Company for the financial year 2025-26. (Annexure-III)

The Board also considered and approved the specific request of Ind-Swift Limited to approve the sale by Ind-Swift Limited of the following assets, which are non-operational and unutilised for quite some time:

S. No.	Property Details & Location	Size
1	Industrial Building, Tehsil Nahan, Distt. Sirmaur	3 Bigha with covered area of 14600 Sq. Feet
2	Showroom, Sec-3, Panchkula	514 Sq. Meters

While approving the Board of the Company also took note that: a) the proceeds from the sale shall be utilised by Ind-Swift Limited for the reduction/repayment of its debt. b) the sale of the said assets shall have no impact on the operations of the Ind-Swift Limited, both presently and post-merger with the Company.

Details as required pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations and SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024, are enclosed as **Annexures**.



## Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



The above information will also be available on the website of the Company at [www.indswiftlabs.com](http://www.indswiftlabs.com).

The Board Meeting commenced at 06:30 P.M and concluded at 07:30 P.M. You are requested to kindly take the same on record.

Thanking you,  
For **IND-SWIFT LABORATORIES LTD.**



**PARDEEP VERMA**  
**VP-CORPORATE AFFAIRS &**  
**COMPANY SECRETARY**  
Encl: a/a



RATTAN KAUR & ASSOCIATES  
CHARTERED ACCOUNTANTS  
SCF: 1, SECTOR: 20-C  
CHANDIGARH: 160020  
Mobile: 9501343300  
Email: carattan@gmail.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to

The Board of Directors  
Ind-Swift Laboratories Ltd.  
SCO 850, Shivalik Enclave  
NAC Manimajra  
Chandigarh

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of **Ind-Swift Laboratories Ltd.** ("the Company") for the Quarter and Nine Months ended 31<sup>st</sup> December 2024 ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (the "Listing Regulations").
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors in their meeting held on 13<sup>th</sup> February, 2025 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules, as amended, read with Circular, issued there under and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of Interim Financial Information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with





RATTAN KAUR & ASSOCIATES  
CHARTERED ACCOUNTANTS  
SCF: 1, SECTOR: 20-C  
CHANDIGARH: 160020  
Mobile: 9501343300  
Email: carattan@gmail.com

standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rattan Kaur & Associates  
Chartered Accountants  
(Regd No: 022513N)



Place: Chandigarh  
Date: 13.02.2025  
UDIN: 25513530BMJOLU3742

Rattan Kaur  
(Partner)  
M. No. 513530



# Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
 Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
 E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
 CIN No. L24232CH1995PLC015553



IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DEC 2024						
CIN L24232CH1995PLC015553						
	Rs. In Lakhs					
Particulars	STANDALONE					
	Quarter Ended 31.12.2024	Quarter Ended 30.09.2024	Quarter Ended 31.12.2023	Nine Month Ended 31.12.2024	Nine Month Ended 31.12.2023	Year Ended 31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Income from Operations:</b>						
Revenue from operations	140.80	270.62	27628.25	3457.03	84558.80	122731.79
Other Income	1381.03	1294.61	711.37	3789.59	2006.36	4531.35
<b>Total Income</b>	<b>1521.83</b>	<b>1565.23</b>	<b>28339.62</b>	<b>7246.61</b>	<b>86565.16</b>	<b>127263.15</b>
<b>EXPENSES:</b>						
a Cost of Materials Consumed	0.00	0.00	15336.44	0.00	43409.77	56117.61
b. Purchase of stock in Trade	36.73	49.85	175.60	2604.41	237.62	2533.24
c. ( Increase) /decrease in FG,WIP & stock in trade	0.00	0.00	(942.52)	0.00	(688.77)	3707.27
d. Employee benefit	616.12	521.74	3568.32	1693.52	11038.88	14888.43
e. Finance Costs	11.36	41.08	2105.41	69.31	6257.55	5109.55
f. Depreciation	24.59	21.65	1355.59	71.23	4062.88	5330.28
g. Other expenditure	369.39	898.92	4066.10	1693.72	12815.54	20488.66
<b>TOTAL EXPENSES</b>	<b>1058.18</b>	<b>1533.24</b>	<b>25664.94</b>	<b>6132.19</b>	<b>77133.47</b>	<b>108175.05</b>
<b>Profit(loss) before exceptional Items and Tax</b>	<b>463.65</b>	<b>31.99</b>	<b>2674.68</b>	<b>1114.42</b>	<b>9431.70</b>	<b>19088.09</b>
Exceptional Items (Income) /loss	0.00	0.00	0.00	0.00	0.00	(38659.00)
<b>Profit(loss) before Tax (After exceptional items)</b>	<b>463.65</b>	<b>31.99</b>	<b>2674.68</b>	<b>1114.42</b>	<b>9431.70</b>	<b>57747.09</b>
<b>Tax Expenses :-</b>						
Current Tax	0.00	0.00	467.32	0.00	1647.91	16088.66
Mat credit Utilisation	0.00	0.00	35.98	0.00	897.50	897.50
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1084.34)
Income Tax Adjustment of Previous Years	0.00	0.00	5.91	0.00	6.25	6.25
<b>Profit/ (Loss) after tax and before share of</b>	<b>463.65</b>	<b>31.99</b>	<b>2165.47</b>	<b>1114.42</b>	<b>6880.04</b>	<b>41839.01</b>
Share of profit (loss) in joint venture	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit (+)/ Loss (-) for the period from continuing operations</b>	<b>463.65</b>	<b>31.99</b>	<b>2165.47</b>	<b>1114.42</b>	<b>6880.04</b>	<b>41839.01</b>
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after Tax)	0.00	0.00	0.00	0.00	0.00	0.00
<b>Net Profit / ( Loss) for the period after tax &amp; Exceptional items)</b>	<b>463.65</b>	<b>31.99</b>	<b>2165.47</b>	<b>1114.42</b>	<b>6880.04</b>	<b>41839.01</b>
<b>Other Comprehensive Income</b>						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	37.48	34.70
<b>Other Comprehensive Income ( Loss) for the period , net of Tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>37.48</b>	<b>34.70</b>
<b>Total Comprehensive Income for the Period</b>	<b>463.65</b>	<b>31.99</b>	<b>2165.47</b>	<b>1114.42</b>	<b>6842.55</b>	<b>41804.31</b>
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						86315.53
EPS (of Rs. 10/- each) (Not annualised)						
Basic	0.78	0.05	3.66	1.89	11.64	70.81
Diluted	0.78	0.05	3.66	1.89	11.64	70.81

Place: Chandigarh  
 Date: 13-02-2025

For Ind Swift Laboratories Ltd

*N.R. Munjal*  
 N.R. Munjal  
 Chairman & Managing Director





RATTAN KAUR & ASSOCIATES

CHARTERED ACCOUNTANTS

SCF: 1, SECTOR: 20-C

CHANDIGARH: 160020

Mobile: 9501343300


Email: carattan@gmail.com

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

**Review Report to**

**The Board of Directors**  
**Ind-Swift Laboratories Ltd.**  
SCO 850, Shivalik Enclave  
NAC Manimajra  
Chandigarh

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results ("the Statement") of **IND-SWIFT LABORATORIES LIMITED** (the "Holding Company") ,its subsidiaries (the Holding company and its subsidiaries together referred to as "the Group") for the quarter & nine months ended 31<sup>st</sup> December, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to



obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 date March 29, 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of:

<u>Particulars</u>	<u>Name of the Company</u>
Subsidiary Companies	Ind Swift Laboratories Inc. USA Fortune (India) Constructions Ltd MJM Remedies Private Limited ISLL Middle East LLC- FZ
Joint Venture	INDIS Healthcare LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results includes the interim financial statements/financial information/financial results of three subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/financial information /financial results reflect total revenue of Rs 725.84 Lakhs and Rs. 1927.86 Lakhs for quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively, total net profit/(loss) before tax of Rs. (571.78) Lakhs and Rs. (1066.19) Lakhs for quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively and total comprehensive income of Rs. (464.19) Lakhs and Rs. (974.17) Lakhs for the quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively as considered in consolidated unaudited financial results.





RATTAN KAUR & ASSOCIATES

CHARTERED ACCOUNTANTS

SCF: 1, SECTOR: 20-C

CHANDIGARH: 160020

Mobile: 9501343300

Email: carattan@gmail.com

7. The consolidated unaudited financial results include the interim financial statements/Financial information/Financial results of INDIS healthcare LLP ( Joint Venture ) which have been reviewed/audited by the auditors whose interim financial statements /Financial information/ Financial results reflect total Net Profit /(Loss) of Rs. 1.16 Lakhs and Rs. (4.74) Lakhs for quarter ended 31.12.2024 and nine months ended 31.12.2024 respectively.

Accordingly to the information and explanations given to us by the Management, these interim financial statements /financial information/financial results are not material to the Group. Our Conclusion on the Statement is not modified in respect of the above matter.

For Rattan Kaur & Associates

Chartered Accountants

FRN: 022513N



Rattan Kaur

(Partner)

M. No. 513530

Place: Chandigarh

Date: 13.02.2025

UDIN: 25513530BMJOLV9006



# Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
 Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
 E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
 CIN No. L24232CH1995PLC015553



IND SWIFT LABORATORIES LTD.						
Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101						
STATEMENT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED 31ST DEC 2024						
CIN L24232CH1995PLC015553						
	Rs. In Lakhs					
	CONSOLIDATED					
Particulars	Quarter Ended 31.12.2024	Quarter Ended 30.09.2024	Quarter Ended 31.12.2023	Nine Month Ended 31.12.2024	Nine Month Ended 31.12.2023	Year Ended 31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Income from Operations:</b>						
Revenue from operations	866.45	1195.68	28751.43	5378.77	88756.50	128089.99
Other Income	1381.22	1300.52	711.39	3795.70	2011.70	4536.75
<b>Total Income</b>	<b>2247.67</b>	<b>2496.20</b>	<b>29462.82</b>	<b>9174.47</b>	<b>90768.20</b>	<b>132626.74</b>
<b>EXPENSES:</b>						
a Cost of Materials Consumed	585.22	781.39	16310.45	1579.95	46666.12	59905.88
b. Purchase of stock in Trade	36.73	49.85	175.60	2604.41	237.62	2533.24
c. ( Increase) /decrease in FG,WIP & stock in trade	0.00	0.00	(942.52)	0.00	(688.77)	3707.27
d. Employee benefit	669.64	580.45	3708.19	1858.75	11356.11	15281.15
e. Finance Costs	11.40	41.12	2105.41	69.40	6257.61	5110.36
f. Depreciation	24.59	21.65	1355.59	71.23	4062.88	5330.28
g. Other expenditure	1028.22	963.38	4330.70	2942.50	13416.95	21241.84
<b>TOTAL EXPENSES</b>	<b>2355.80</b>	<b>2437.83</b>	<b>27043.42</b>	<b>9126.24</b>	<b>81308.53</b>	<b>113110.01</b>
<b>Profit(loss) before exceptional Items and Tax</b>	<b>(108.13)</b>	<b>58.36</b>	<b>2419.40</b>	<b>48.23</b>	<b>9459.67</b>	<b>19516.73</b>
Exceptional Items (Income) /loss	0.00	0.00	0.00	0.00	0.00	(38659.00)
<b>Profit(loss) before Tax (After exceptional Items)</b>	<b>(108.13)</b>	<b>58.36</b>	<b>2419.40</b>	<b>48.23</b>	<b>9459.67</b>	<b>58175.72</b>
<b>Tax Expenses :-</b>						
Current Tax	(107.59)	18.45	424.61	(92.02)	1680.15	16211.14
Mat credit Utilisation	0.00	0.00	35.98	0.00	897.50	897.50
Deferred Tax	0.00	0.00	0.00	0.00	0.00	(1084.34)
Income Tax Adjustment of Previous Years	0.00	0.00	5.91	0.00	6.25	6.25
<b>Profit/ (Loss) after tax and before share of</b>	<b>(0.54)</b>	<b>39.92</b>	<b>1952.89</b>	<b>140.25</b>	<b>6875.77</b>	<b>42145.17</b>
Share of profit (loss) in joint venture	1.16	1.42	(11.01)	(4.74)	(43.95)	(49.01)
<b>Profit (+)/ Loss (-) for the period from continuing operations</b>	<b>0.62</b>	<b>41.34</b>	<b>1941.88</b>	<b>135.51</b>	<b>6831.82</b>	<b>42096.16</b>
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00	0.00	0.00
<b>Profit (+)/ Loss (-) from discontinuing operations(after Tax)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>Net Profit /( Loss) for the period after tax &amp; Exceptional Items)</b>	<b>0.62</b>	<b>41.34</b>	<b>1941.88</b>	<b>135.51</b>	<b>6831.82</b>	<b>42096.16</b>
<b>Other Comprehensive Income</b>						
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	0.00	0.00	0.00	37.48	34.70
<b>Other Comprehensive Income ( Loss) for the period , net of Tax</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>37.48</b>	<b>34.70</b>
<b>Total Comprehensive Income for the Period</b>	<b>0.62</b>	<b>41.34</b>	<b>1941.88</b>	<b>135.51</b>	<b>6794.34</b>	<b>42061.46</b>
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	5908.69	5908.69	5908.69	5908.69	5908.69	5908.69
Reserve excluding revaluation reserves						95247.83
EPS (of Rs. 10/- each) (Not annualised)						
Basic	0.00	0.07	3.29	0.23	11.56	71.24
Diluted	0.00	0.07	3.29	0.23	11.56	71.24

For Ind Swift Laboratories Ltd

*N.R. Munjal*  
 N.R. Munjal  
 Chairman & Managing Director  
 CHANDIGARH  
 Ind-Swift Laboratories Ltd.

Place: Chandigarh  
 Date: 13-02-2025



# Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



## Notes: -

1. The standalone and consolidated unaudited financial results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 13<sup>th</sup> February, 2025.
2. The standalone and consolidated financial statements for the quarter ended and nine months ended 31.12.2024 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
3. Details of amount considered as the exceptional items are as under:

## STANDALONE

(Rs. In Lakhs)

Particulars	Quarter ended 31.12.2024	Quarter ended 30.09.2024	Quarter ended 31.12.2023	Nine Months ended 31.12.2024	Nine Months ended 31.12.2023	Year ended 31.03.2024*
Exceptional Items	0.00	0.00	0.00	0.00	0.00	38659.00

## CONSOLIDATED

(Rs. In Lakhs)

Particulars	Quarter ended 31.12.2024	Quarter ended 30.09.2024	Quarter ended 31.12.2023	Nine Months ended 31.12.2024	Nine Months ended 31.12.2023	Year ended 31.03.2024*
Exceptional Items	0.00	0.00	0.00	0.00	0.00	38659.00

\* An exceptional gain of INR 386.59 Crores as shown in financial year ended 31<sup>st</sup> March, 2024 was on account of the slump sale of the API and CRAMS Business of the Company.

4. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company.
5. The consolidated financial results include the financial results of the parent company Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture:
  - a) Ind-Swift Laboratories Inc., USA (Subsidiary)
  - b) Fortune (India) Constructions Limited (Subsidiary)
  - c) Indis Healthcare LLP (Joint Venture)
  - d) MJM Remedies Private Limited (Subsidiary)
  - e) ISLL Middle East LLC-FZ (Subsidiary)

Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'.

6. No adjustment has been made in respect of Deferred Taxes & Current Tax as per IND AS-12, as the same would be provided at the year end.





# Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553




7. During the quarter under review the Company has not issued any Non-Convertible Debt Securities.
8. The Company has filed first Motion Petition for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Ltd. The Hon'ble NCLT, Chandigarh Bench vide their order dated 03.01.2025 approved the first motion application and directed the company to conduct the meeting of Equity Shareholders and Unsecured Creditors which is scheduled to be held on 22<sup>nd</sup> February, 2025.
9. The previous period figures have been re-grouped and re-classified wherever necessary.
10. The Company is exclusively in the Pharmaceutical Business segment.

Place: Chandigarh  
Date: 13<sup>th</sup> February, 2025

For Ind Swift Laboratories Limited

*N.R. Munjal*

N.R. Munjal  
Chairman & Managing Director





# Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



## Annexure II

### Details under Regulation 30 of Listing Regulations read with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024

S No	Particulars	Details
1	<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Re-appointment of Secretarial Auditor under the provisions of Section 204 of the Companies Act, 2013 and the requirements under SEBI (LODR) Regulations, 2015.
2	<b>Date of appointment</b>	13 <sup>th</sup> February, 2025.
3	<b>Term of appointment</b>	1 (One) year starting from 01.04.2024 to 31.03.2025, on such terms and conditions as may be agreed.
4	<b>Brief profile (in case of appointment)</b>	Sh. Vishal Arora is a peer reviewed Practising Company Secretary with membership no 4566 and COP no 3645. He specialises in Company Law, Securities Laws, Secretarial Audit, FEMA etc. along with other specializations. Sh. Vishal Arora has been conducting secretarial audits of various listed entities and unlisted companies.



# Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920,5061850, 5061853  
E-mail : info@indswiflabs.com Website : www.indswiflabs.com  
CIN No. L24232CH1995PLC015553



## Annexure III

### Details under Regulation 30 of Listing Regulations read with SEBI circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024

S No	Particulars	Details
1	<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Re-appointment of Internal Auditors under the provisions of Section 138 of the Companies Act, 2013 and the requirements under SEBI (LODR) Regulations, 2015
2	<b>Date of appointment</b>	13 <sup>th</sup> February, 2025.
3	<b>Term of appointment</b>	1 (One) year starting from 01.04.2025 to 31.03.2026, on such terms and conditions as may be agreed.
4	<b>Brief profile (in case of appointment)</b>	M/s. Jain & Associates (FRN: 001361N), registered with the Institute of Chartered Accountants of India (ICAI), have more than 50 years of experience in the areas of statutory audit and internal audit. The Firm has been conducting internal audits of various listed entities and unlisted companies. The firm specializes in helping to conduct internal audits, identifying process gaps and strengthening internal controls.